← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT06531863

Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance

Trial Parameters

Condition Mood Disturbance
Sponsor Auburn University
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 64
Sex ALL
Min Age 18 Years
Max Age 50 Years
Start Date 2024-09-30
Completion 2025-05-01
Interventions
CurcuminEpigallocatechin GallatePlacebo

Brief Summary

The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)

Eligibility Criteria

Inclusion Criteria: * Adults age 18-50 * Depression subscale score of \>9/21 on the DASS-21 * No change in medications or supplements over the past 3 months * Can read and speak English Exclusion Criteria: * Currently consume curcumin or green tea daily * Currently, pregnant, nursing, or trying to become pregnant * Currently diagnosed with a perimenopausal disorder

Related Trials